326 related articles for article (PubMed ID: 29210835)
61. Short Communication: Bioequivalence of Tenofovir and Emtricitabine After Coencapsulation with the Proteus Ingestible Sensor.
Ibrahim ME; Brooks KM; Castillo-Mancilla JR; McHugh C; Morrow M; Brothers J; MaWhinney S; Hosek S; Huhn G; Anderson PL
AIDS Res Hum Retroviruses; 2018 Oct; 34(10):835-837. PubMed ID: 30047286
[TBL] [Abstract][Full Text] [Related]
62. Brief Report: Tenofovir-Associated Nephrotoxicity Among a US National Historical Cohort of HIV-Infected Veterans: Risk Modification by Concomitant Antiretrovirals.
LaFleur J; Bress AP; Esker S; Knippenberg K; Crook J; Nyman H; Bedimo R; Tebas P; Rosenblatt L
J Acquir Immune Defic Syndr; 2018 Mar; 77(3):325-330. PubMed ID: 29210830
[TBL] [Abstract][Full Text] [Related]
63. Persistence on HIV preexposure prophylaxis medication over a 2-year period among a national sample of 7148 PrEP users, United States, 2015 to 2017.
Coy KC; Hazen RJ; Kirkham HS; Delpino A; Siegler AJ
J Int AIDS Soc; 2019 Feb; 22(2):e25252. PubMed ID: 30775846
[TBL] [Abstract][Full Text] [Related]
64. Small-area spatial-temporal changes in pre-exposure prophylaxis (PrEP) use in the general population and among men who have sex with men in the United States between 2012 and 2018.
Mouhanna F; Castel AD; Sullivan PS; Kuo I; Hoffman HJ; Siegler AJ; Jones JS; Mera Giler R; McGuinness P; Kramer MR
Ann Epidemiol; 2020 Sep; 49():1-7. PubMed ID: 32951802
[TBL] [Abstract][Full Text] [Related]
65. Baseline Characteristics Explain Differences in Effectiveness of Randomization to Daily Oral TDF/FTC PrEP Between Transgender Women and Cisgender Men Who Have Sex With Men in the iPrEx Trial.
Mehrotra ML; Westreich D; McMahan VM; Glymour MM; Geng E; Grant RM; Glidden DV
J Acquir Immune Defic Syndr; 2019 Jul; 81(3):e94-e98. PubMed ID: 31192894
[No Abstract] [Full Text] [Related]
66. Pre-exposure Prophylaxis Use by Breastfeeding HIV-Uninfected Women: A Prospective Short-Term Study of Antiretroviral Excretion in Breast Milk and Infant Absorption.
Mugwanya KK; Hendrix CW; Mugo NR; Marzinke M; Katabira ET; Ngure K; Semiyaga NB; John-Stewart G; Muwonge TR; Muthuri G; Stergachis A; Celum CL; Baeten JM
PLoS Med; 2016 Sep; 13(9):e1002132. PubMed ID: 27676257
[TBL] [Abstract][Full Text] [Related]
67. Results from a Pre-exposure Prophylaxis Demonstration Project for At-risk Cisgender Women in the United States.
Blumenthal J; Jain S; He F; Amico KR; Kofron R; Ellorin E; Stockman JK; Psaros C; Ntim GM; Chow K; Anderson PL; Haubrich R; Corado K; Moore DJ; Morris S; Landovitz RJ
Clin Infect Dis; 2021 Oct; 73(7):1149-1156. PubMed ID: 33864370
[TBL] [Abstract][Full Text] [Related]
68. Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073.
Zhang Y; Clarke W; Marzinke MA; Piwowar-Manning E; Beauchamp G; Breaud A; Hendrix CW; Cloherty GA; Emel L; Rose S; Hightow-Weidman L; Siegel M; Shoptaw S; Fields SD; Wheeler D; Eshleman SH
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438932
[TBL] [Abstract][Full Text] [Related]
69. Efficacy and safety of long-acting cabotegravir versus oral tenofovir disoproxil fumarate-emtricitabine as HIV pre-exposure prophylaxis: A systematic review and meta-analysis.
Chen X; Li J; Kou L; Xie X; Wei D; Li Y
Rev Med Virol; 2023 Jul; 33(4):e2460. PubMed ID: 37198721
[TBL] [Abstract][Full Text] [Related]
70. PrEParing for Preexposure Prophylaxis.
Zappas MP; Foreman RM
J Dr Nurs Pract; 2020 Mar; 13(1):3-8. PubMed ID: 32701461
[TBL] [Abstract][Full Text] [Related]
71. Dolutegravir with tenofovir disoproxil fumarate-emtricitabine as HIV postexposure prophylaxis in gay and bisexual men.
McAllister JW; Towns JM; Mcnulty A; Pierce AB; Foster R; Richardson R; Carr A
AIDS; 2017 Jun; 31(9):1291-1295. PubMed ID: 28301425
[TBL] [Abstract][Full Text] [Related]
72. The impact of intimate partner violence on PrEP adherence among U.S. Cisgender women at risk for HIV.
Anderson KM; Blumenthal J; Jain S; Sun X; Amico KR; Landovitz R; Zachek CM; Morris S; Moore DJ; Stockman JK
BMC Public Health; 2024 May; 24(1):1461. PubMed ID: 38822300
[TBL] [Abstract][Full Text] [Related]
73. Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.
Tetteh RA; Yankey BA; Nartey ET; Lartey M; Leufkens HG; Dodoo AN
Drug Saf; 2017 Apr; 40(4):273-283. PubMed ID: 28130774
[TBL] [Abstract][Full Text] [Related]
74. Daily HIV pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate-emtricitabine reduced Streptococcus and increased Erysipelotrichaceae in rectal microbiota.
Dubé MP; Park SY; Ross H; Love TMT; Morris SR; Lee HY
Sci Rep; 2018 Oct; 8(1):15212. PubMed ID: 30315206
[TBL] [Abstract][Full Text] [Related]
75. Safety review of tenofovir disoproxil fumarate/emtricitabine pre-exposure prophylaxis for pregnant women at risk of HIV infection.
Stalter RM; Pintye J; Mugwanya KK
Expert Opin Drug Saf; 2021 Nov; 20(11):1367-1373. PubMed ID: 33998936
[No Abstract] [Full Text] [Related]
76. Implementation of a community pharmacy-based pre-exposure prophylaxis service: a novel model for pre-exposure prophylaxis care.
Tung EL; Thomas A; Eichner A; Shalit P
Sex Health; 2018 Nov; 15(6):556-561. PubMed ID: 30401342
[TBL] [Abstract][Full Text] [Related]
77. Adherence to Pre-Exposure Prophylaxis for HIV Prevention in a Clinical Setting.
Montgomery MC; Oldenburg CE; Nunn AS; Mena L; Anderson P; Liegler T; Mayer KH; Patel R; Almonte A; Chan PA
PLoS One; 2016; 11(6):e0157742. PubMed ID: 27333000
[TBL] [Abstract][Full Text] [Related]
78. Preexposure Prophylaxis for Prevention of HIV Acquisition Among Adolescents: Clinical Considerations, 2020.
Tanner MR; Miele P; Carter W; Valentine SS; Dunville R; Kapogiannis BG; Smith DK
MMWR Recomm Rep; 2020 Apr; 69(3):1-12. PubMed ID: 32324724
[TBL] [Abstract][Full Text] [Related]
79. Costs and benefits of on-demand HIV preexposure prophylaxis in MSM.
Durand-Zaleski I; Mutuon P; Charreau I; Tremblay C; Rojas D; Pialoux G; Chidiac C; Capitant C; Spire B; Cotte L; Chas J; Meyer L; Molina JM;
AIDS; 2018 Jan; 32(1):95-102. PubMed ID: 29210777
[TBL] [Abstract][Full Text] [Related]
80. Going global: the adoption of the World Health Organization's enabling recommendation on oral pre-exposure prophylaxis for HIV.
Hodges-Mameletzis I; Dalal S; Msimanga-Radebe B; Rodolph M; Baggaley R
Sex Health; 2018 Nov; 15(6):489-500. PubMed ID: 30496718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
